Group 1: Research Basic Information - Research object: Aier Eye Hospital [16] - Industry: Medical services [16] - Reception time: January 22, 2026 [16] - Reception staff: Chairman Chen Bang, Secretary of the Board Wu Shijun, and staff from the Board Office [16] Group 2: Detailed Research Institutions - Securities companies: China Merchants Securities (represented by Liang Guangkai and Zhang Yuxin), Ping An Securities (represented by Ni Yidao and Wang Yuchang), Yangtze Securities (represented by Gao Chenxing) [17] - Fund management company: Hunan Medical Development Private Equity Fund (represented by Zhang Qingzhu) [17] Group 3: Main Content Refractive New Technology Application - The company's refractive technology is in sync with international standards and leading in China, offering a wide range of surgical procedures for personalized and precise medical services [22] - In the past two years, the company has introduced upgraded procedures such as ICL V5, Femto LASIK Pro, Femto LASIK 4.0, and All - optical plastic surgery, meeting diverse needs [23] - The new procedures have achieved a significant first - mover advantage. For example, the Femto LASIK Pro has completed over 10,000 surgeries by January 2026, accounting for about 25% of the national total [23] - The new procedures have shorter operation times, better visual quality, and have reversed the downward trend of average prices [24] Domestic Ophthalmic Industry Competition Pattern - The Chinese ophthalmic medical service market shows a pattern of "diverse co - existence, local concentration, and long - term concentration towards the leading players" [25] - Competition is long - term and regional, with the industry having strong geographical and brand - dependent characteristics [25] - The company focuses on building core competitiveness in medical safety, patient service, talent echelon, and technological innovation [26] - The company builds a systematic service system to meet the diverse needs of different patient groups [26] Commercial Insurance in Ophthalmic Services - The company's current insurance payment structure includes medical insurance and commercial health insurance, with the latter having great potential [27] - With the aging population and increasing medical service demand, the synergy between commercial insurance and medical institutions is expected to increase [28] Artificial Intelligence Application - The company attaches great importance to the application of new technologies and will strengthen integration and innovation to provide multi - level ophthalmic services [29] Internationalization Progress - The company has overseas layouts in Europe, Southeast Asia, and the United States, with overseas business growing well and accounting for about 13% of total revenue [29] - The company will expand overseas based on local market conditions, aiming to form a scale effect and achieve two - way empowerment between domestic and overseas businesses [29][30]

Core Viewpoint - The company maintains international synchronization and domestic leadership in refractive technology, advocating the principle that "the best is what suits" while offering personalized and precise medical services [1] Group 1: Technological Advancements - The company has introduced various upgraded surgical techniques in the past two years, including ICLV5, all-laser femtosecond Pro, all-laser femtosecond 4.0, and all-light plastic surgery, to meet diverse patient needs [1] - The all-laser femtosecond Pro technique, introduced in mid-2025, achieved a cumulative surgical volume of over 10,000 cases by January 2026, accounting for approximately 25% of the total in the domestic market [1] - The company is a significant promoter and contributor to the all-light plastic surgery technique, enhancing patient experience with shorter surgery times and better visual quality [1] Group 2: Competitive Advantages - The company leverages its network, expert, brand, and popular science advantages to accelerate the promotion of new technologies, reinforcing its first-mover advantage in the domestic ophthalmology market [1] - The company plays a multiplicative role for upstream manufacturers, which is challenging to achieve in fragmented markets [1]

Group 1: Current Technology and Market Position - The company maintains international synchronization and domestic leadership in refractive technology, offering a variety of personalized and precise medical services [1] - As of January 2026, the company has completed over 10,000 surgeries using the all-laser Pro technique, accounting for approximately 25% of the total surgeries in China [1] - The introduction of new surgical techniques has led to shorter operation times and improved visual quality, reversing the trend of declining average prices [2] Group 2: Competitive Landscape - The Chinese ophthalmology market exhibits a "multi-dimensional coexistence" pattern, with a tendency for long-term concentration among leading players [3] - The company emphasizes patient-centered care and avoids aggressive price wars that compromise medical quality and brand reputation [3] - The company focuses on building core competencies in medical safety, patient experience, talent development, and technological innovation [3] Group 3: Future Opportunities and Innovations - The potential for commercial health insurance is significant, especially as the aging population increases demand for medical services [5] - The company is committed to exploring the application of artificial intelligence in its services, aiming to provide comprehensive eye care for all age groups [6] - The company's overseas business accounts for approximately 13% of total revenue, with significant growth potential in international markets [7]

Core Insights - The event organized by Shenzhen Stock Exchange aimed to deepen investors' understanding of Aier Eye Hospital's (300015) listed company status and its role in the ophthalmology sector [1] Group 1: Company Overview - Aier Eye Hospital maintains international synchronization and domestic leadership in refractive technology, offering a wide range of surgical procedures that are continuously upgraded [2] - The company emphasizes personalized medical services based on the principle that "the suitable is the best," leading to increased patient recognition of advanced techniques like "All Light Plastic," "All-Femto 4.0," and "All-Femto Pro" [2] Group 2: Business Development - Aier's business structure optimization has resulted in a steady increase in average pricing, demonstrating effective measures against market saturation [2] - The company's vision care business has developed a comprehensive system from prevention to treatment, enhancing its core competitiveness through an integrated medical education and research platform [2] Group 3: Market Expansion - Investors are particularly interested in Aier's international expansion, with the company acknowledging the vast potential of the overseas ophthalmology market [2] - Aier plans to pursue internationalization more actively and cautiously, focusing on healthy growth of existing overseas institutions while enhancing its medical network in surrounding regions [2]

Core Insights - The company reported a revenue of 17.484 billion yuan for the first three quarters of 2025, representing a year-on-year growth of 7.25%, with a net profit of 3.119 billion yuan, up 0.2% [1] - In Q3, the company achieved a revenue of 5.977 billion yuan, marking a growth of 3.83% despite a high base from the previous year [1] - The successful operation of several large ophthalmology centers indicates significant progress in the company's "1+8+N" strategy, enhancing long-term competitiveness [1] Business Structure Optimization - The company has optimized its business structure, particularly in refractive surgery, by focusing on technological upgrades, leading to a significant increase in the application of new surgical techniques [1] - The average transaction price in refractive services has increased by over 5% due to the rising proportion of new surgical techniques [1] - The anticipated approval of the ICL V5 new type of lens by the end of the year is expected to further enhance the company's business structure [1] Cataract and Vision Services - The company is adapting to changes in the market driven by reforms in medical insurance payment methods, focusing on both "popularization" and "upgrading" of cataract surgeries [2] - The volume of cataract surgeries has continued to grow, benefiting more patients, while the company is also enhancing its offerings in functional lenses and advanced surgical techniques [2] - In vision services, the company is expanding its adult eyewear services and transitioning towards "visual health management," which has shown promising results in pilot hospitals [2] Multidisciplinary Approach - The company is leveraging its comprehensive ophthalmology advantages by establishing multidisciplinary diagnostic and treatment (MDT) groups to address complex eye conditions [3] - A proactive approach has been taken to manage presbyopia by setting up specialized clinics, targeting the growing elderly population [3] Future Outlook - The company is well-positioned to meet the long-term growth in ophthalmic treatment demand due to aging populations and increasing awareness of visual health [3] - The ongoing optimization of business structure and technological upgrades are expected to provide resilience against industry fluctuations [3]

Core Viewpoint - Aier Eye Hospital Group reported a revenue of 17.484 billion yuan for the first three quarters of 2025, reflecting a year-on-year growth of 7.25%, while the net profit attributable to shareholders increased by 0.2% to 3.119 billion yuan [1] Group 1: Financial Performance - The company achieved a revenue of 5.977 billion yuan in the third quarter, marking a year-on-year growth of 3.83% despite a high base from the previous year [1] - The revenue for the first three quarters reached 17.484 billion yuan, with a net profit of 3.119 billion yuan, indicating a stable financial performance [1] Group 2: Business Structure Optimization - The company has seen a significant optimization in its business structure, particularly in refractive surgery, with new surgical techniques like "All-Laser Femto" and "All-Optical" being more widely adopted [2] - The average transaction price for refractive services has increased by over 5% due to the rising proportion of new surgical techniques [2] - The cataract surgery volume has continued to grow, benefiting more patients while the company adapts to changes in medical insurance payment methods [2] Group 3: Vision Care Services - The company is enhancing its myopia prevention and control services for adolescents and expanding adult eyewear services towards "visual health management" [3] - A multidisciplinary diagnostic and treatment (MDT) group has been established to address complex eye diseases, particularly focusing on presbyopia management [3] - The market for presbyopia management is expected to grow significantly, driven by increasing demand and the aging population [3] Group 4: Industry Outlook - The overall demand for eye care services is projected to grow due to aging populations and increasing awareness of visual quality [4] - The company is strategically positioned to meet diverse patient needs through business structure optimization and technological upgrades [4]

Core Insights - Aier Eye Hospital reported a revenue of 17.484 billion yuan for the first nine months of the year, a year-on-year increase of 7.25%, while net profit decreased by 9.76% to 3.114 billion yuan [1] - The slowdown in profit growth is attributed to increased depreciation and labor costs from the implementation of the "1+8+N" strategy, which has led to higher expenses but does not affect cash flow [1] - The company is making significant progress in its "1+8+N" strategy, with multiple eye centers now operational, enhancing resource allocation efficiency [1] Financial Performance - Revenue for the first nine months reached 17.484 billion yuan, up 7.25% year-on-year [1] - Net profit for the same period was 3.114 billion yuan, down 9.76% year-on-year [1] - Cash flow from operating activities increased by 18.14% year-on-year, indicating strong operational performance despite profit decline [1] Strategic Developments - The "1+8+N" strategy is yielding tangible results, with several eye centers in cities like Changsha, Shanghai, and Guangzhou now operational [1] - The company is enhancing its organizational structure and optimizing regional resource integration to improve management efficiency [1] - Aier Eye Hospital is focusing on digital upgrades to boost operational management efficiency [1] Industry Trends - The chairman emphasizes the importance of long-term strategies and addressing challenges in the eye care industry, including improving medical technology and service quality [2] - New surgical techniques such as all-light plastic and all-femtosecond procedures are being promoted, leading to improved patient outcomes and stabilizing service prices [2] - The company is addressing the growing demand for age-related eye diseases by establishing specialized clinics and services [3] Future Outlook - Aier Eye Hospital plans to continue advancing surgical techniques, with new implant technologies expected to be approved by year-end [2] - The company is transitioning to a "full lifecycle service" model, offering comprehensive eye health services tailored to individual needs [3] - An upcoming investor reception event aims to showcase the company's advancements in AI, new technologies, and services [3]

Core Insights - The company reported a revenue of 11.507 billion yuan for the first half of 2025, representing a year-on-year growth of 9.12%, with a net profit attributable to shareholders of 2.051 billion yuan, showing a slight increase of 0.05% [1] - The second quarter revenue was 5.481 billion yuan, reflecting a year-on-year growth of 2.47%, while the net profit attributable to shareholders decreased by 12.97% to 1.001 billion yuan [1] Revenue Breakdown - Refractive and optical income experienced rapid year-on-year growth, while cataract income saw single-digit growth. Refractive project revenue reached 4.618 billion yuan, up 11.14%, with a slight decline in gross margin compared to the first half of 2024 [2] - Cataract project revenue was 1.781 billion yuan, growing by 2.64%, with a decrease in gross margin as well [2] - Optical project revenue amounted to 2.720 billion yuan, marking a year-on-year increase of 14.73%, with a decline in gross margin [2] Profitability Metrics - The company's gross margin for the first half of 2025 was 48.56%, down 0.88 percentage points year-on-year, while the net margin was 19.29%, down 1.66 percentage points [2] - The sales expense ratio decreased to 9.15%, down 1.47 percentage points year-on-year, while the management expense ratio slightly increased [2] Future Outlook - The company maintains a "recommended" rating, adjusting profit forecasts for 2025-2027 to net profits of 3.721 billion, 4.325 billion, and 5.102 billion yuan respectively, due to the implementation of DRG and artificial lens procurement policies [3] - With macroeconomic policies aimed at stimulating the economy, the performance in the consumer healthcare sector is expected to recover, positioning the company as a resilient leader in the industry [3]

Group 1: Industry Overview - The ophthalmology sector is experiencing significant performance differentiation among listed companies, with a competitive landscape evolving rapidly [1][2] - The Chinese ophthalmology medical service market is projected to reach 223.1 billion yuan in 2024, growing at 11.05% year-on-year, with private institutions holding a 42% market share [3] - The refractive and cataract surgery segments account for 47% of the overall market, with refractive surgery alone reaching a market size of 73 billion yuan [3] Group 2: Company Performance - Aier Eye Hospital leads the industry with a revenue of 11.507 billion yuan, showcasing strong market competitiveness, while Huaxia and Puri Eye Hospitals follow with revenues exceeding 1.4 billion yuan [1] - Aier Eye Hospital's net profit stands at 2.051 billion yuan, but its growth rate has slowed to 0.05%, while He Eye Hospital achieved a remarkable net profit growth of 84.19% [1] - Puri Eye Hospital reported a significant decline in net profit by 66.12%, indicating challenges in profitability [1] Group 3: Competitive Dynamics - The competition in the ophthalmology sector is intensifying, with an increasing number of private eye hospitals and supportive government policies encouraging private capital participation [2] - The cataract surgery segment is facing revenue pressures due to policy changes, including centralized procurement and DRG/DIP payment reforms, leading to revenue declines for several companies [4] - The industry is entering a "red ocean" phase, with rapid increases in capacity and competition among private eye hospitals [4][5] Group 4: Strategic Responses - Companies are focusing on mergers and acquisitions to expand their market presence, with Aier Eye Hospital acquiring three companies in the first half of 2025 [6] - Huaxia Eye Hospital is enhancing its management and service processes while accelerating the construction of hospitals and optical centers [6] - He Eye Hospital is expanding its franchise model, signing 23 new contracts in the first half of 2025 [6] Group 5: Technological Innovation - Technological innovation is becoming a key competitive advantage, particularly in the refractive surgery segment, where new techniques are being rapidly adopted [7][8] - Aier Eye Hospital's refractive project revenue grew by 11.14%, driven by the promotion of new surgical techniques [7] - The demand for personalized vision correction among the Z generation is pushing for rapid innovation in refractive surgery technologies [8][9] Group 6: Market Challenges - The expansion trend in the ophthalmology market is reversing, with some less competitive hospitals closing due to increased competition and economic pressures [5] - Companies face challenges in balancing expansion with cost control, particularly regarding goodwill and operational costs [6] - The market for refractive surgery is characterized by a need for patient education and awareness, as patients often rely on personal recommendations rather than solely on physician advice [10]

Core Viewpoint - The ophthalmology medical industry is experiencing a slowdown in the growth of refractive surgery revenue, with many companies reporting single-digit growth rates in this segment, while a few are still achieving double-digit growth. Group 1: Industry Overview - The refractive surgery business, a significant revenue source for private ophthalmology institutions, has shown a general trend of slowing growth in recent years [1] - Among five listed ophthalmology companies in A-shares, three reported refractive project revenue growth at single-digit levels or below in the first half of the year [1] - Specific growth figures include: - Puyi Eye Hospital (301239.SZ) with a 4.13% increase to 720 million yuan, accounting for 49% of total revenue [1] - He’s Eye Hospital (301103.SZ) with a 3.26% increase to 135 million yuan, accounting for 24% of total revenue [1] - Guangzheng Eye Hospital (002524.SZ) with a 0.32% increase to 142 million yuan, accounting for 32.71% of total revenue [1] - Aier Eye Hospital (300015.SZ) and Huaxia Eye Hospital (301267.SZ) are exceptions, achieving revenue growth rates of 11.4% and 13.75%, respectively [1] Group 2: Company Strategies - Aier Eye Hospital attributes its revenue growth in refractive projects to the acceptance of new surgical techniques such as All-Laser LASIK and the expansion of its medical network, enhancing patient coverage [3] - Puyi Eye Hospital is focusing on introducing authoritative expert teams and updating high-end diagnostic equipment to cultivate new growth points in the competitive refractive and vision care market [3] Group 3: Market Demand and Trends - The current refractive surgery patient population is divided into two categories: those with essential needs due to academic or professional requirements and those seeking aesthetic improvements [4] - Despite a stable demand from the essential needs group, the decision-making cycle for non-essential consumers is lengthening due to macroeconomic factors [4] - There is significant unmet demand in the refractive surgery market, with approximately 700 million myopic patients in China, but only about 1 million undergoing surgery annually [4] - The Z generation shows a personalized and urgent demand for vision correction, driving innovation and iteration in refractive surgery technologies [4] - Aierkon has introduced new refractive surgery solutions, such as All-Laser LASIK, which allows for personalized treatment based on various eye data [4] Group 4: Technology Adoption - Aierkon's All-Laser LASIK equipment has seen over 50,000 surgeries performed since its launch at the 2023 China International Import Expo, with over 100 hospitals equipped nationwide [5] - The company emphasizes the need for continued market education to enhance the penetration of new technologies [5]